-
Je něco špatně v tomto záznamu ?
Treatment of high risk prostate cancer with combined radiotherapy and hormonal treatment- results and identification of factors influencing outcome
J. Kubes, K. Dedeckova, J. Cvek, V. Vondrácek, J. Dvorak, S. Argalacsová, M. Navrátil, J. Buril,
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
PubMed
24065481
Knihovny.cz E-zdroje
- MeSH
- adenokarcinom mortalita patologie terapie MeSH
- celková dávka radioterapie MeSH
- chemoradioterapie * MeSH
- dospělí MeSH
- hormonální protinádorové látky terapeutické užití MeSH
- konformní radioterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- nádory prostaty mortalita patologie terapie MeSH
- následné studie MeSH
- neoadjuvantní terapie MeSH
- prognóza MeSH
- prospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- stupeň nádoru MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: The aim of this work was to prospectively analyze the outcome of combined hormonal treatment and radical radiotherapy in high risk non metastatic prostate cancer patients (T1=4, N0-1, M0). METHODS: Between April 2003 and December 2007 196 patients with high risk prostate cancer were treated with curative intent. The treatment consisted of 2-month neoadjuvant hormonal treatment (LHRH analog), radical radiotherapy (68-78 Gy, conformal technique) and an optional 2-year adjuvant hormonal treatment. RESULTS: The median follow up time was 59 months. Fiveyear overall survival was 86% and 5-year biochemical disease free survival (DFS) 70%. Factors found to be statistically significant relative to outcomes were Gleason score (p=0.017), initial PSA value (p=0.039) and adjuvant hormonal treatment (p=0.035). There was no significant association between radiotherapy dose or volume and biochemical DFS (bDFS). Late genitourinary and gastrointestinal toxicity was acceptable. CONCLUSION: Treatment combining hormonal therapy and radical radiotherapy can be recommended for this subgroup of prostate cancer patients. Adjuvant hormonal treatment should also be used.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14050793
- 003
- CZ-PrNML
- 005
- 20140411120132.0
- 007
- ta
- 008
- 140401s2013 gr f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)24065481
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Kubes, J
- 245 10
- $a Treatment of high risk prostate cancer with combined radiotherapy and hormonal treatment- results and identification of factors influencing outcome / $c J. Kubes, K. Dedeckova, J. Cvek, V. Vondrácek, J. Dvorak, S. Argalacsová, M. Navrátil, J. Buril,
- 520 9_
- $a PURPOSE: The aim of this work was to prospectively analyze the outcome of combined hormonal treatment and radical radiotherapy in high risk non metastatic prostate cancer patients (T1=4, N0-1, M0). METHODS: Between April 2003 and December 2007 196 patients with high risk prostate cancer were treated with curative intent. The treatment consisted of 2-month neoadjuvant hormonal treatment (LHRH analog), radical radiotherapy (68-78 Gy, conformal technique) and an optional 2-year adjuvant hormonal treatment. RESULTS: The median follow up time was 59 months. Fiveyear overall survival was 86% and 5-year biochemical disease free survival (DFS) 70%. Factors found to be statistically significant relative to outcomes were Gleason score (p=0.017), initial PSA value (p=0.039) and adjuvant hormonal treatment (p=0.035). There was no significant association between radiotherapy dose or volume and biochemical DFS (bDFS). Late genitourinary and gastrointestinal toxicity was acceptable. CONCLUSION: Treatment combining hormonal therapy and radical radiotherapy can be recommended for this subgroup of prostate cancer patients. Adjuvant hormonal treatment should also be used.
- 650 _2
- $a adenokarcinom $x mortalita $x patologie $x terapie $7 D000230
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a hormonální protinádorové látky $x terapeutické užití $7 D018931
- 650 12
- $a chemoradioterapie $7 D059248
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a nádory prostaty $x mortalita $x patologie $x terapie $7 D011471
- 650 _2
- $a celková dávka radioterapie $7 D011879
- 650 _2
- $a konformní radioterapie $7 D020266
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dedeckova, K $u -
- 700 1_
- $a Cvek, J $u -
- 700 1_
- $a Vondrácek, V $u -
- 700 1_
- $a Dvorak, J $u -
- 700 1_
- $a Argalacsová, S $u - $7 gn_A_00008309
- 700 1_
- $a Navrátil, M $u -
- 700 1_
- $a Buril, J $u -
- 773 0_
- $w MED00005361 $t Journal of B.U.ON. : official journal of the Balkan Union of Oncology $x 1107-0625 $g Roč. 18, č. 3 (2013), s. 669-74
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24065481 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140401 $b ABA008
- 991 __
- $a 20140411120223 $b ABA008
- 999 __
- $a ok $b bmc $g 1017929 $s 849373
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 18 $c 3 $d 669-74 $i 1107-0625 $m Journal of Balkan Union of Oncology $n J BUON $x MED00005361
- LZP __
- $a Pubmed-20140401
